Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02772003
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA)
vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or
progresses over a long period of time. Vaccines made from DNA may help the body build an
effective immune response to kill cancer cells that express HCV infection.
vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or
progresses over a long period of time. Vaccines made from DNA may help the body build an
effective immune response to kill cancer cells that express HCV infection.
Intervention
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid
Condition
Chronic Hepatitis, Hepatitis C Infection
Investigators
Jeffrey M Jacobson